These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34975146)

  • 1. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.
    Shoemaker AH; Silver HJ; Buchowski M; Slaughter JC; Yanovski JA; Elfers C; Roth CL; Abuzzahab MJ
    Int J Obes (Lond); 2022 Mar; 46(3):623-629. PubMed ID: 34975146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
    Roth CL; Perez FA; Whitlock KB; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ
    Diabetes Obes Metab; 2021 Feb; 23(2):363-373. PubMed ID: 33026160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
    Basolo A; Burkholder J; Osgood K; Graham A; Bundrick S; Frankl J; Piaggi P; Thearle MS; Krakoff J
    Metabolism; 2018 Aug; 85():116-125. PubMed ID: 29596853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
    Perez FA; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ; Roth CL
    Diabetes Obes Metab; 2021 Jul; 23(7):1532-1541. PubMed ID: 33651438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
    Golubic R; Kennet J; Parker V; Robertson D; Luo D; Hansen L; Jermutus L; Ambery P; Ryaboshapkina M; Surakala M; Laker RC; Venables M; Koulman A; Park A; Evans M
    Diabetes Obes Metab; 2024 Jul; 26(7):2634-2644. PubMed ID: 38562018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.
    van Schaik J; Begijn DGA; van Iersel L; Vergeer Y; Hoving EW; Peeters B; van Santen HM
    Obes Facts; 2020; 13(4):361-370. PubMed ID: 32781455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in energy balance following exenatide administration.
    Bradley DP; Kulstad R; Racine N; Shenker Y; Meredith M; Schoeller DA
    Appl Physiol Nutr Metab; 2012 Oct; 37(5):893-9. PubMed ID: 22735035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Oxytocin for Obesity.
    Plessow F; Kerem L; Wronski ML; Asanza E; O'Donoghue ML; Stanford FC; Eddy KT; Holmes TM; Misra M; Thomas JJ; Galbiati F; Muhammed M; Sella AC; Hauser K; Smith SE; Holman K; Gydus J; Aulinas A; Vangel M; Healy B; Kheterpal A; Torriani M; Holsen LM; Bredella MA; Lawson EA
    NEJM Evid; 2024 May; 3(5):EVIDoa2300349. PubMed ID: 38815173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides.
    Rigamonti AE; Casnici C; Marelli O; De Col A; Tamini S; Lucchetti E; Tringali G; De Micheli R; Abbruzzese L; Bortolotti M; Cella SG; Sartorio A
    Nutr Res; 2018 Apr; 52():71-79. PubMed ID: 29530622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
    Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
    Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
    Friedrichsen M; Breitschaft A; Tadayon S; Wizert A; Skovgaard D
    Diabetes Obes Metab; 2021 Mar; 23(3):754-762. PubMed ID: 33269530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.
    Verdich C; Flint A; Gutzwiller JP; Näslund E; Beglinger C; Hellström PM; Long SJ; Morgan LM; Holst JJ; Astrup A
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4382-9. PubMed ID: 11549680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
    Ishøy PL; Knop FK; Broberg BV; Bak N; Andersen UB; Jørgensen NR; Holst JJ; Glenthøj BY; Ebdrup BH
    Diabetes Obes Metab; 2017 Feb; 19(2):162-171. PubMed ID: 27717222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
    Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.